Exelixis
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1851 Harbor Bay Pkwy, Alameda, Californi...Phone Number
(650) 837-7000Website
www.exelixis.comRevenue
$2.4 BillionStock Symbol
EXELIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
1
1
About Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.Explore more
Exelixis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Exelixis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Exelixis is spiking on competitors!
Funding: Get notified immidiatlly once Exelixis has new funding data
Congratulate Masked Content for being promoted to Masked Content at Exelixis
Exelixis, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Exelixis recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Exelixis has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Exelixis launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Exelixis had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Exelixis as Masked Content
Find 3 more new buyers
Compare Similar Companies to Exelixis
Compare insights from companies similar to Exelixis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Exelixis
$2.4B
1K - 5K
Public
$118.3M
1994
Christopher SennerExecutive Vice President & Chief Financial Officer
Company Profile Activity
Activity Insights
Exelixis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Exelixis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Exelixis.
Exelixis financials insights
Gather financial insights about Exelixis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2000
Stock Offering
$118.3M
Exelixis Tech Stack
A closer look at the technologies used by Exelixis
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Event
Product Marketing, Events, Business Intelligence, Analytics & Insights, Sales, Pharmaceuticals, Field /Outside Sales, Field Marketing, Operations, Sales Enablement, Sales Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Exelixis News & Media
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating. NEW YORK, Aug. 17, 2026 /PRNewswire/ -- A revenue miss, not an earnings miss, drove Exelixis, Inc....EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of EXEL shareholders. NEW YORK, Aug. 11,...Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)
On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the Company lowered and narrowed that revenue outlook -- and the stock fell. NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) reiterated its full-year 2026 financial...Exelixis Q2 Earnings Call Highlights
Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program f
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Exelixis
Sign Up For FreeTo access detailed company insights
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatm... Read More
